Abstract:
The invention relates to the field of cancer diagnosis, more specific to the monitoring of disease development during and after treatment. The invention comprises a method for determining minimal residual disease comprising amplifying nucleic acid molecules using at least one primer reactive with a common gene segment and further comprising identifying malignancy-specific nucleic acid sequences by hybridising with a fluorogenic probe specifically and selectively reactive with said malignancy-specific nucleic acid sequences.
Abstract:
The present invention is concerned with a Feline herpesvirus (FHV) mutant comprising a heterologous gene introduced into a section of the FHV genome. The invention also relates to a vector vaccine comprising such an FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and induces an adequate immune response in an inoculated host against both FHV and the feline pathogen.